Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Pathog ; 18(7): e1010688, 2022 07.
Article in English | MEDLINE | ID: mdl-35793357

ABSTRACT

Herpes simplex virus type 1 (HSV-1) is a common virus of mankind and HSV-1 infections are a significant cause of blindness. The current antiviral treatment of herpes infection relies on acyclovir and related compounds. However, acyclovir resistance emerges especially in the long term prophylactic treatment that is required for prevention of recurrent herpes keratitis. Earlier we have established antiviral siRNA swarms, targeting sequences of essential genes of HSV, as effective means of silencing the replication of HSV in vitro or in vivo. In this study, we show the antiviral efficacy of 2´-fluoro modified antiviral siRNA swarms against HSV-1 in human corneal epithelial cells (HCE). We studied HCE for innate immunity responses to HSV-1, to immunostimulatory cytotoxic double stranded RNA, and to the antiviral siRNA swarms, with or without a viral challenge. The panel of studied innate responses included interferon beta, lambda 1, interferon stimulated gene 54, human myxovirus resistance protein A, human myxovirus resistance protein B, toll-like receptor 3 and interferon kappa. Our results demonstrated that HCE cells are a suitable model to study antiviral RNAi efficacy and safety in vitro. In HCE cells, the antiviral siRNA swarms targeting the HSV UL29 gene and harboring 2´-fluoro modifications, were well tolerated, induced only modest innate immunity responses, and were highly antiviral with more than 99% inhibition of viral release. The antiviral effect of the 2'-fluoro modified swarm was more apparent than that of the unmodified antiviral siRNA swarm. Our results encourage further research in vitro and in vivo on antiviral siRNA swarm therapy of corneal HSV infection, especially with modified siRNA swarms.


Subject(s)
Herpes Simplex , Herpesvirus 1, Human , Acyclovir/metabolism , Acyclovir/pharmacology , Antiviral Agents/metabolism , Antiviral Agents/pharmacology , Epithelial Cells/metabolism , Herpes Simplex/genetics , Herpes Simplex/therapy , Herpesvirus 1, Human/physiology , Humans , RNA, Double-Stranded/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Virus Replication/genetics
2.
Viruses ; 12(12)2020 12 13.
Article in English | MEDLINE | ID: mdl-33322225

ABSTRACT

Acyclovir is the drug of choice for the treatment of herpes simplex virus (HSV) infections. Acyclovir-resistant HSV strains may emerge, especially during long-term drug use, and subsequently cause difficult-to-treat exacerbations. Previously, we set up a novel treatment approach, based on enzymatically synthesized pools of siRNAs, or siRNA swarms. These swarms can cover kilobases-long target sequences, reducing the likelihood of resistance to treatment. Swarms targeting the UL29 essential gene of HSV-1 have demonstrated high efficacy against HSV-1 in vitro and in vivo. Here, we assessed the antiviral potential of a UL29 siRNA swarm against circulating strains of HSV-1, in comparison with acyclovir. All circulating strains were sensitive to both antivirals, with the half-maximal inhibitory concentrations (IC50) in the range of 350-1911 nM for acyclovir and 0.5-3 nM for the UL29 siRNA swarm. Additionally, we showed that an acyclovir-resistant HSV-1, devoid of thymidine kinase, is highly sensitive to UL29 siRNA treatment (IC50 1.0 nM; Imax 97%). Moreover, the detected minor variations in the RNAi target of the HSV strains had no effect on the potency or efficacy of UL29 siRNA swarm treatment. Our findings support the development of siRNA swarms for the treatment of HSV-1 infections, in order to circumvent any potential acyclovir resistance.


Subject(s)
Acyclovir/pharmacology , DNA-Binding Proteins/genetics , Herpes Simplex/virology , Herpesvirus 1, Human/drug effects , Herpesvirus 1, Human/genetics , RNA Interference , RNA, Small Interfering/genetics , Viral Proteins/genetics , Acyclovir/therapeutic use , Animals , Chlorocebus aethiops , Dose-Response Relationship, Drug , Drug Resistance, Viral/drug effects , Drug Resistance, Viral/genetics , Herpes Simplex/therapy , Herpesvirus 1, Human/classification , Herpesvirus 1, Human/isolation & purification , Humans , Inhibitory Concentration 50 , Vero Cells
3.
Antiviral Res ; 182: 104916, 2020 10.
Article in English | MEDLINE | ID: mdl-32798603

ABSTRACT

Chemical modifications of small interfering (si)RNAs are used to enhance their stability and potency, and to reduce possible off-target effects, including immunogenicity. We have earlier introduced highly effective antiviral siRNA swarms against herpes simplex virus (HSV), targeting 653 bp of the essential UL29 viral gene. Here, we report a method for enzymatic production and antiviral use of 2'-fluoro-modified siRNA swarms. Utilizing the RNA-dependent RNA polymerase from bacteriophage phi6, we produced 2'-F-siRNA swarms containing either all or a fraction of modified adenosine, cytidine or uridine residues in the antisense strand of the UL29 target. The siRNA containing modified pyrimidines demonstrated high resistance to RNase A and the antiviral potency of all the UL29-specific 2'-F-siRNA swarms was 100-fold in comparison with the unmodified counterpart, without additional cytotoxicity. Modest stimulation of innate immunity signaling, including induced expression of both type I and type III interferons, as well as interferon-stimulated gene 54, by 2'-F-cytidine and 2'-F-uridine modified siRNA swarms occurred at early time points after transfection while the 2'-F-adenosine-containing siRNA was similar to the unmodified antiviral siRNA swarm in this respect. The antiviral efficacy of the 2'-F-siRNA swarms and the elicited cellular innate responses did not correlate suggesting that innate immunity pathways do not significantly contribute to the observed enhanced antiviral activity of the modified siRNAs. The results support further applications of enzymatically produced siRNA molecules with incorporated adenosine nucleotides, carrying fluoro-modification on ribose C2' position, for further antiviral studies in vitro and in vivo.


Subject(s)
Antiviral Agents/pharmacology , Cell Survival , Herpesvirus 1, Human/drug effects , Immunity, Innate , RNA, Small Interfering/pharmacology , RNA-Dependent RNA Polymerase/metabolism , Adenosine/metabolism , Bacteriophage phi 6/enzymology , Cell Line , Cell Line, Tumor , Cytidine/metabolism , DNA-Binding Proteins/antagonists & inhibitors , Herpesvirus 1, Human/immunology , Humans , RNA, Small Interfering/chemical synthesis , Transfection , Uridine/metabolism , Viral Proteins/antagonists & inhibitors
4.
J Histochem Cytochem ; 67(7): 511-522, 2019 07.
Article in English | MEDLINE | ID: mdl-31009269

ABSTRACT

The extracellular matrix proteoglycan decorin is well-known for its oncosuppressive activity. Here, decorin expression was examined in human vulva carcinoma tissue samples and in primary and commercial cell lines representing this malignant disease. Furthermore, the effect of adenovirus-mediated decorin cDNA (Ad-DCN) transduction on the viability, proliferation, and the expression and activity of the epidermal growth factor receptor (ErbB/HER) family members of the cell lines were investigated. Using in situ hybridization and immunohistochemistry for decorin, it was demonstrated that malignant cells in human vulva carcinoma tissues lack decorin expression. This result was true independently on tumor stage, grade or human papillomavirus status. RT-qPCR analyses showed that the human vulva carcinoma cell lines used in this study were also negative for decorin expression. Transduction of the cell lines with Ad-DCN caused a marked reduction in cell viability, while the proliferation of the cells was not affected. Experiments examining potential mechanisms behind the oncosuppressive effect of Ad-DCN transduction revealed that ErbB2/HER2 expression and activity in carcinoma cells were markedly downregulated. In conclusion, the results of this study showed that human vulva carcinoma cells lack decorin expression, and that Ad-DCN transduction of these cells induces oncosuppressive activity in part via downregulation of ErbB2/HER2.


Subject(s)
Decorin/genetics , Gene Expression Regulation, Neoplastic , Genital Neoplasms, Female/genetics , Transduction, Genetic , Vulva/pathology , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , DNA, Complementary/genetics , ErbB Receptors/genetics , Female , Genital Neoplasms, Female/metabolism , Genital Neoplasms, Female/pathology , Humans , Middle Aged , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/genetics , Sequestosome-1 Protein/metabolism
5.
J Histochem Cytochem ; 63(9): 710-20, 2015 09.
Article in English | MEDLINE | ID: mdl-26001829

ABSTRACT

Decorin is generally recognized as a tumor suppressing molecule. Nevertheless, although decorin has been shown to be differentially expressed in malignant tissues, it has often remained unclear whether, in addition to non-malignant stromal cells, cancer cells also express it. Here, we first used two publicly available databases to analyze the current information about decorin expression and immunoreactivity in normal and malignant human colorectal tissue samples. The analyses demonstrated that decorin expression and immunoreactivity may vary in cancer cells of human colorectal tissues. Therefore, we next examined decorin expression in normal, premalignant and malignant human colorectal tissues in more detail using both in situ hybridization and immunohistochemistry for decorin. Our results invariably demonstrate that malignant cells within human colorectal cancer tissues are devoid of both decorin mRNA and immunoreactivity. Identical results were obtained for cells of neuroendocrine tumors of human colon. Using RT-qPCR, we showed that human colon cancer cell lines are also decorin negative, in accordance with the above in vivo results. Finally, we demonstrate that decorin transduction of human colon cancer cell lines causes a significant reduction in their colony forming capability. Thus, strategies to develop decorin-based adjuvant therapies for human colorectal malignancies are highly rational.


Subject(s)
Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Decorin/metabolism , Carcinogenesis , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/pathology , Cell Line, Tumor , Colon/cytology , Colon/pathology , Colorectal Neoplasms/genetics , DNA Methylation , Databases, Protein , Decorin/genetics , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , In Situ Hybridization , Neuroendocrine Tumors/genetics , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/pathology , Promoter Regions, Genetic/genetics , Protein Transport , RNA, Messenger/genetics , RNA, Messenger/metabolism
6.
PLoS One ; 8(10): e76190, 2013.
Article in English | MEDLINE | ID: mdl-24146840

ABSTRACT

Decorin, a multifunctional small leucine-rich extracellular matrix proteoglycan, has been shown to possess potent antitumour activity. However, there is some uncertainty whether different cancer cells express decorin in addition to non-malignant stromal cells. In this study we clarified decorin expression by human bladder cancer cells both in vivo and in vitro. In addition, the effect of adenovirus-mediated decorin expression on human bladder cancer cells in vitro was examined. We first demonstrated using the publicly available GeneSapiens databank that decorin gene expression is present in both normal and malignant human bladder tissues. However, when we applied in situ hybridization with digoxigenin-labeled RNA probes for decorin on human bladder carcinoma tissue samples derived from a large radical cystectomy patient cohort (n = 199), we unambiguously demonstrated that invasive and non-invasive bladder carcinoma cells completely lack decorin mRNA. The cancer cells were also negative for decorin immunoreactivity. Instead, decorin expression was localized solely to original non-malignant stromal areas of bladder tissue. In accordance with the aforementioned results, human bladder cancer cells in vitro were also negative for decorin expression as shown by RT-qPCR analyses. The lack of decorin expression by bladder cancer cells was shown not to be due to the methylation of the proximal promoter region of the decorin gene. When bladder cancer cells were transfected with a decorin adenoviral vector, their proliferation was significantly decreased. In conclusion, we have shown that human bladder cancer cells are totally devoid of decorin expression. We have also shown that adenovirus-mediated decorin gene transduction of human bladder cancer cell lines markedly inhibits their proliferation. Thus, decorin gene delivery offers new potential therapeutic tools in urothelial malignancies.


Subject(s)
Decorin/deficiency , Gene Expression Regulation, Neoplastic , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/therapy , Urothelium/metabolism , Urothelium/pathology , Adenoviridae/metabolism , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Cell Proliferation , DNA Methylation/genetics , Decorin/genetics , Female , HEK293 Cells , Humans , Male , Middle Aged , Neoplasm Invasiveness , Promoter Regions, Genetic/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transduction, Genetic , Urinary Bladder Neoplasms/pathology
7.
Arch Virol ; 154(1): 159-62, 2009.
Article in English | MEDLINE | ID: mdl-19034605

ABSTRACT

Dasheen mosaic virus (DsMV) is an important constraint to production of cocoyam (Xanthosoma spp.) in Nicaragua. Reverse transcription polymerase chain reaction was used to amplify the coat protein (CP) region from ten Nicaraguan DsMV isolates. These isolates showed high nucleotide identity to DsMV isolates from the USA, eastern Asia and Australasia. All Nicaraguan isolates except one shared a tandem repeat in the N-terminus of the CP. Phylogenetic analyses showed that the Nicaraguan isolates formed two distinct subgroups correlated with geographic origin. This can be explained by different origins of the cocoyam genotypes grown in these regions.


Subject(s)
Potyvirus/genetics , Xanthosoma/virology , Capsid Proteins/genetics , Molecular Sequence Data , Nicaragua , Phylogeny , Plant Leaves/virology , Potyvirus/isolation & purification , RNA, Viral/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...